Ricolinostat is not a highly selective HDAC6 inhibitor

被引：7
|
作者：
Medard, Guillaume [1 ]
Sheltzer, Jason M. [2 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Chem, Prote Core Facil, Athens, Greece
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
NATURE CANCER | 2023年 / 4卷 / 06期
关键词：
D O I：
10.1038/s43018-023-00582-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：807 / 808
页数：2
相关论文
共 50 条
  • [1] Ricolinostat is not a highly selective HDAC6 inhibitor
    Guillaume Médard
    Jason M. Sheltzer
    Nature Cancer, 2023, 4 : 807 - 808
  • [2] Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor
    Jose Silva
    Jiyang Yu
    Kevin Kalinsky
    Nature Cancer, 2023, 4 : 809 - 811
  • [3] Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor
    Silva, Jose
    Yu, Jiyang
    Kalinsky, Kevin
    NATURE CANCER, 2023, 4 (06) : 809 - 811
  • [4] Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat.
    Pan, Qingfei
    Zeleke, Tizita
    Chiuzan, Cody
    Onishi, Maika
    Alvarez, Mariano
    Honan, Erin
    Yang, Min
    Chia, Pei Ling
    Mukhopadhyay, Partha
    Kelly, Sean
    Wu, Ruby
    Fenn, Kathleen
    Trivedi, Meghna
    Accordino, Melissa
    Crew, Katherine
    Hershman, Dawn
    Maurer, Matthew
    Jones, Simon
    Califano, Andrea
    Kalinsky, Kevin
    Yu, Jiyang
    Silva, Jose
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant antimelanoma activity in vitro and in vivo
    Cheng, Fengdong
    Andressa, Sodre
    Chen, Jie
    Villagra, Alejandro
    Woods, David
    Weber, Jeffrey
    Quayle, Steven
    Simon, Jones
    Sotomayor, Eduardo
    CANCER RESEARCH, 2017, 77
  • [6] Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
    Cosenza, Maria
    Civallero, Monica
    Marcheselli, Luigi
    Sacchi, Stefano
    Pozzi, Samantha
    APOPTOSIS, 2017, 22 (06) : 827 - 840
  • [7] Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
    Maria Cosenza
    Monica Civallero
    Luigi Marcheselli
    Stefano Sacchi
    Samantha Pozzi
    Apoptosis, 2017, 22 : 827 - 840
  • [8] Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
    Zeleke, Tizita Z.
    Pan, Qingfei
    Chiuzan, Codruta
    Onishi, Maika
    Li, Yuxin
    Tan, Haiyan
    Alvarez, Mariano J.
    Honan, Erin
    Yang, Min
    Chia, Pei Ling
    Mukhopadhyay, Partha
    Kelly, Sean
    Wu, Ruby
    Fenn, Kathleen
    Trivedi, Meghna S.
    Accordino, Melissa
    Crew, Katherine D.
    Hershman, Dawn L.
    Maurer, Matthew
    Jones, Simon
    High, Anthony
    Peng, Junmin
    Califano, Andrea
    Kalinsky, Kevin
    Yu, Jiyang
    Silva, Jose
    NATURE CANCER, 2023, 4 (02) : 257 - +
  • [9] In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties.
    Cheng, Fengdong
    Laino, Andressa Sodre
    Wang, Hongwei
    Chen, Jie
    Villagra, Alejandro
    Woods, David Michael
    Weber, Jeffrey S.
    Quayle, Steven
    Jones, Simon S.
    Sotomayor, Eduardo M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
    Tizita Z. Zeleke
    Qingfei Pan
    Codruta Chiuzan
    Maika Onishi
    Yuxin Li
    Haiyan Tan
    Mariano J. Alvarez
    Erin Honan
    Min Yang
    Pei Ling Chia
    Partha Mukhopadhyay
    Sean Kelly
    Ruby Wu
    Kathleen Fenn
    Meghna S. Trivedi
    Melissa Accordino
    Katherine D. Crew
    Dawn L. Hershman
    Matthew Maurer
    Simon Jones
    Anthony High
    Junmin Peng
    Andrea Califano
    Kevin Kalinsky
    Jiyang Yu
    Jose Silva
    Nature Cancer, 2023, 4 : 257 - 275
12345